Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.29 USD

88.29
5,843,461

+0.21 (0.24%)

Updated Oct 30, 2024 04:00 PM ET

Pre-Market: $88.12 -0.17 (-0.19%) 9:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mallinckrodt's Stannsoporfin Gets Complete Response Letter

Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.

    John Blank headshot

    Don't Worry About An Inverted Yield Curve...YET

    The U.S. economy should remain out of recession until 2020.

      Alnylam Completes Enrollment in Phase III Givosiran Study

      Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.

        Pacira (PCRX) Rides High on Robust Exparel Performance

        Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.

          Allergan Falls on FDA's Rejection of Uterine Fibroids Drug

          FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.

            Infinity Focuses on Developing IPI-549 for Solid Tumors

            Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.

              Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

              AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

                Alexion's BLA for ALXN1210 Gets Priority Review From FDA

                The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                  China Biologic Products (CBPO) Looks Good: Stock Adds 8.7% in Session

                  China Biologic Products (CBPO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

                    The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor

                    The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor

                      Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer

                      Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.

                        Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

                        Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.

                          John Blank headshot

                          Time for Jackson Hole: Global Week Ahead

                          The world???s central bankers are going to be in Jackson Hole, Wyoming speaking to Jerome Powell and the rest of the Fed contingent. Mr. Powell himself will speak Friday morning.

                            Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

                            Is (GILD) Outperforming Other Medical Stocks This Year?

                              Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

                              Is (GILD) Outperforming Other Medical Stocks This Year?

                                Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

                                Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

                                  Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead

                                  Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead

                                    Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

                                    Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

                                      Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

                                      Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

                                        Tracey Ryniec headshot

                                        Lessons from a Legendary Value Investor

                                        Value investors are rare. Find out what it takes to be one and how to find value stocks from one of the greats.

                                          Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

                                          Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

                                            Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit

                                            Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.

                                              Shire, Shionogi File NDA for Intuniv for Adults in Japan

                                              Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

                                                Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

                                                Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

                                                  Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

                                                  Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.